Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Teva Pharmaceuticals Industries Limited Q4 2025 earnings conference call. My name is Alex. I'll be coordinating today's call. If you'd like to ask a question at the end of the presentation, you may press star followed by one on your telephone keypad. I'm going to hand it over to Chris Stevo, SVP, Investor Relations. Please go ahead. Thank you, Alex. Good morning and good afternoon, everyone. Thank you for joining us on our fourth quarter call. Before I turn it over to our CEO, Richard Francis, I just want to remind everyone that we will be making forward-looking statements on this call. Any statements we make are only as of today, and we undertake no obligation to update those statements subsequently. And if you have any questions about our forward-looking statements, feel free to see the appropriate sections in our SEC forms 10-K and 10-Q. With that, Richard Francis. Thank you, Chris. Good morning, good afternoon, everybody. Great to have you on the call. Also on the call with me today will be Dr. Eric Hughes, head of R&D and chief medical officer, who will be walking you through some exciting developments in our pipeline. And then Eli Khalif, my CFO, who will go through the Q4 and the full year results. So starting with, as I always do, the pivot to growth strategy and the progress we've made over the last three years. As you know, the foundation is the four pillars, Delivering our growth engines, I think you'll see in the results that we continue to have great momentum around our innovative portfolio of Stedo, Yosedi, and Ejovi. That's some great progress on our innovation, so step-up innovation. You'll see that we filed Olanzapine last year and completed the recruitment of the diary study for dual action rescue inhaler and started our phase three, ...